Nuvation Bio Inc.
NYSE:NUVBBiotechnology
Healthcare
$3.81 +1.03%
+$0.06 today
- Market cap
- $1.34B
- Beta
- 1.56
- P/E (TTM)
- -12.8
- EPS (TTM)
- -$0.42
52W Low $1.81High $9.75
Volume 9.92M
Average 4.07M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$173.43M
FY 2025 · Annual
Investing Cash Flow
$99.52M
FY 2025 · Annual
-18.9% YoYFinancing Cash Flow
$202.53M
FY 2025 · Annual
+61088.8% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (86.85M) | (104.2M) | (75.8M) | (567.94M) | (204.63M) |
| Depreciation & Amortization | 184K | 199K | 222K | 683K | 1.74M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 9.27M | 16.29M | 19.51M | 32.28M | 35.89M |
| Change in Working Capital | 4.79M | (3.45M) | 540K | (12.51M) | (11.98M) |
| Accounts Receivables | (1.95M) | 554K | (1.22M) | (12.59M) | (3.07M) |
| Inventory | 0 | 0 | 0 | 0 | (11.41M) |
| Accounts Payables | 1.86M | (1.79M) | 70K | (1.65M) | 3.13M |
| Other Working Capital | 4.88M | (2.22M) | 1.69M | 1.74M | (630K) |
| Other Non-Cash Items | 4.41M | (4.95M) | (12.47M) | 417.08M | 5.55M |
| Operating Cash Flow | (68.19M) | (96.11M) | (68M) | (130.41M) | (173.43M) |
| Capital Expenditures | (282K) | (370K) | (69K) | (162K) | (354K) |
| Acquisitions (Net) | 0 | 0 | 0 | 12.43M | 0 |
| Purchases of Investments | (609.3M) | (520.31M) | (703.37M) | (339.65M) | (354.42M) |
| Sales of Investments | 154.91M | 584.12M | 712.35M | 450.08M | 462.29M |
| Other Investing Activities | 0 | 13K | 14K | 0 | 0 |
| Investing Cash Flow | (454.67M) | 63.46M | 8.92M | 122.7M | 99.52M |
| Debt Repayment | 0 | 0 | 0 | (4.55M) | 191.11M |
| Common Stock Issued | 0 | 0 | 0 | 4.89M | 11.42M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 625.53M | 1.33M | 628K | 0 | 0 |
| Financing Cash Flow | 625.53M | 1.33M | 628K | 331K | 202.54M |
| Effect of Forex Changes | 0 | 0 | 0 | 453K | (265K) |
| Net Change in Cash | 102.67M | (31.32M) | (58.45M) | (6.93M) | 128.36M |
| Free Cash Flow | (68.47M) | (96.48M) | (68.07M) | (130.58M) | (173.78M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$204.6M
+ D&A$1.7M
+ Stock-Based Comp$35.9M
+ Deferred Tax$0
- Working Capital-$12.0M
+ Other Non-Cash$5.5M
= Operating Cash Flow-$173.4M
- Capex-$354.0K
= Free Cash Flow-$173.8M
Analysis
FY2025 free cash flow is -$173.8M. FCF conversion is 84.9% of net income. Operating cash flow was -$173.4M, with capex of -$354.0K. The largest bridge item is Stock-Based Comp at $35.9M.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Nov 4, 2026 | |
| 10-Q | Quarterly report | Nov 4, 2026 | |
| 4 | Statement of changes in beneficial ownership | Aug 21, 2026 | |
| 8-K | Current report | Aug 6, 2026 | |
| 10-Q | Quarterly report | Aug 6, 2026 |
Does NUVB generate free cash flow?
Nuvation Bio Inc. (NUVB) generated -$173.78M of free cash flow in fiscal 2025.
How much operating cash flow does NUVB produce?
Operating cash flow was -$173.43M, before capital expenditures of $354,000.00.
Continue the stock analysis
Jump to another research area for this company.